There are 2137 resources available
724P - A prospective phase II study of gemcitabine plus platinum in combination with bevacizumab for metastatic renal medullary and collecting duct carcinoma (GETUG-AFU 24, BEVABEL trial)
Presenter: Constance Thibault
Session: E-Poster Display
Resources:
Abstract
725P - Prognostic values of PD-L1 expression and CD8 infiltration phenotype in metastatic and recurrent renal cell carcinoma: An exploratory analysis of the ARCHERY study
Presenter: Toyonori Tsuzuki
Session: E-Poster Display
Resources:
Abstract
726P - Collecting duct and renal medullary carcinoma: A population based analysis
Presenter: Jeffrey Graham
Session: E-Poster Display
Resources:
Abstract
727P - Cabozantinib (Cabo) concentration (Cmin) association with toxicity (tox) and treatment failure in metastatic renal cell carcinoma (mRCC) patients: The MONICA study
Presenter: Luigi Cerbone
Session: E-Poster Display
Resources:
Abstract
728P - Primary resistance (PrR) versus acquired resistance (AcR) to immune checkpoint inhibitors (ICI) in first-line metastatic renal cell carcinoma (mRCC)
Presenter: Annalisa Guida
Session: E-Poster Display
Resources:
Abstract
729P - Prognostic value of PD-L1 status in the primary lesion as a risk factor for developing metastatic disease in localized renal cell carcinoma: A subgroup analysis of the ARCHERY study
Presenter: Masahiro Nozawa
Session: E-Poster Display
Resources:
Abstract
730P - Interim analysis of CASSIOPE: A real-world study of cabozantinib for the treatment of advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy in Europe
Presenter: Giuseppe Procopio
Session: E-Poster Display
Resources:
Abstract
731P - The impact of proton pump inhibitors on pazopanib exposure
Presenter: Stefanie Krens
Session: E-Poster Display
Resources:
Abstract
732P - Cabozantinib in non-clear cell metastatic renal cell carcinoma and sarcomatoid renal cell carcinoma: Real-world data from the CABOREAL study
Presenter: Aude Fléchon
Session: E-Poster Display
Resources:
Abstract
733P - Quality of life assessment in renal cell carcinoma phase II and III clinical trials published between 2010 and 2020
Presenter: Veronica Mollica
Session: E-Poster Display
Resources:
Abstract